Axsome Therapeutics, Inc. (AXSM)

NGM – Цена в реальном времени. Валюта: USD

215.27

-0.50 (-0.23%)

Рынок открыт: Aug 12, 2026, 12:42 PM EDT

215.35

-0.42 (-0.19%)

Предыдущая сессия: Aug 11, 2026, 7:52 PM EDT

11.08.2026

Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues

AXSM's Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales drive year-over-year revenues.

11.08.2026

Axsome Therapeutics Q2 Earnings Review: I Just Can't See The Value Proposition

Axsome Therapeutics, Inc. reported Q2 2026 net product revenue growth of 46% year-on-year, but rising SG&A costs mostly offset commercial gains. Auvelity drove most revenues, benefiting from new Alzheimer's agitation indication and expanded sales force, yet profitability remains elusive. Management reiterates ambitious ~$8bn peak sales target for Auvelity, but current revenue trajectory and market dynamics cast doubt on achievability.

11.08.2026

Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results

Axsome Therapeutics Inc (NASDAQ:AXSM) on Monday posted downbeat results for the second quarter.

10.08.2026

Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call Transcript

10.08.2026

Axsome (AXSM) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

10.08.2026

Axsome Therapeutics (AXSM) Reports Q2 Loss, Misses Revenue Estimates

Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.99 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.92 per share a year ago.

10.08.2026

Axsome Therapeutics Q2 Earnings Call Highlights

Axsome Therapeutics NASDAQ: AXSM reported second-quarter 2026 net product revenue of $218 million, up 46% from a year earlier, as sales of AUVELITY and SUNOSI increased and prescription demand for SYMBRAVO continued to build.

Видео

No Data

There is no data to display

Пресс-релизы

10.08.2026

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Total 2Q 2026 net product revenue of $218.4 million, representing 46% year-over-year growth AUVELITY® 2Q 2026 net product sales of $180.3 million, representing 51% year-over-year growth SUNOSI® 2Q 2026 net product revenue of $35.8 million, representing 20% year-over-year growth SYMBRAVO® 2Q 2026 net product sales of $2.3 million AUVELITY launched for treatment of agitation associated with dementia due to Alzheimer's disease in June 2026 NDA submission for AXS-12 for cataplexy in narcolepsy accepted by the FDA with PDUFA target action date of May 1, 2027 FOCUS-2 and FOCUS-3 Phase 3 trials of solriamfetol in children and adolescents with ADHD initiated Company to host conference call today at 8:00 AM Eastern NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced financial results for the second quarter of 2026 and provided a general business update. “The second quarter was highly productive for Axsome.

Axsome Therapeutics, Inc. (AXSM)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Axsome Therapeutics, Inc. (AXSM)

Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues

Axsome Therapeutics Q2 Earnings Review: I Just Can't See The Value Proposition

Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results

Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call Transcript

Axsome (AXSM) Reports Q2 Earnings: What Key Metrics Have to Say

Axsome Therapeutics (AXSM) Reports Q2 Loss, Misses Revenue Estimates

Axsome Therapeutics Q2 Earnings Call Highlights

Видео

No Data

Пресс-релизы

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues

Axsome Therapeutics Q2 Earnings Review: I Just Can't See The Value Proposition

Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results

Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call Transcript

Axsome (AXSM) Reports Q2 Earnings: What Key Metrics Have to Say

Axsome Therapeutics (AXSM) Reports Q2 Loss, Misses Revenue Estimates

Axsome Therapeutics Q2 Earnings Call Highlights

Видео

No Data

Пресс-релизы

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Search stocks

Axsome Therapeutics, Inc. (AXSM)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Axsome Therapeutics, Inc. (AXSM)

Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues

Axsome Therapeutics Q2 Earnings Review: I Just Can't See The Value Proposition

Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results

Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call Transcript

Axsome (AXSM) Reports Q2 Earnings: What Key Metrics Have to Say

Axsome Therapeutics (AXSM) Reports Q2 Loss, Misses Revenue Estimates

Axsome Therapeutics Q2 Earnings Call Highlights

Видео

No Data

Пресс-релизы

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues

Axsome Therapeutics Q2 Earnings Review: I Just Can't See The Value Proposition

Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results

Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call Transcript

Axsome (AXSM) Reports Q2 Earnings: What Key Metrics Have to Say

Axsome Therapeutics (AXSM) Reports Q2 Loss, Misses Revenue Estimates

Axsome Therapeutics Q2 Earnings Call Highlights

Видео

No Data

Пресс-релизы

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update